

Anne Peters Harmel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7429674/publications.pdf>

Version: 2024-02-01

143
papers

22,952
citations

24978

57
h-index

11030

137
g-index

148
all docs

148
docs citations

148
times ranked

19722
citing authors

#	ARTICLE	IF	CITATIONS
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	1.3	69
2	Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100111.	1.5	26
3	9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S125-S143.	4.3	534
4	Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 424-434.	2.4	27
5	6. Glycemic Targets: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S83-S96.	4.3	388
6	3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S39-S45.	4.3	74
7	5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:<i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S60-S82.	4.3	177
8	Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study. <i>Diabetes Care</i> , 2021, 44, 67-74.	4.3	10
9	The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 960-968.	4.3	21
10	The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3430.	1.7	44
11	Function and Emotion in Everyday Life With Type 1 Diabetes (FEEL-T1D): Protocol for a Fully Remote Intensive Longitudinal Study. <i>JMIR Research Protocols</i> , 2021, 10, e30901.	0.5	22
12	Changes in mood and healthâ€related quality of life in Look AHEAD 6 years after termination of the lifestyle intervention. <i>Obesity</i> , 2021, 29, 1294-1308.	1.5	5
13	Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2632-2642.	2.2	30
14	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.	4.3	244
15	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.	2.9	128
16	Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodiumâ€Glucose Cotransporter 2 Inhibitor. <i>Diabetes Spectrum</i> , 2021, 34, 42-51.	0.4	4
17	Specialized Technology Education for Pumps & Pens in Underserved Populations with Diabetes (STEPP-UP). <i>Diabetes Technology and Therapeutics</i> , 2021, , .	2.4	1
18	Extended-Release Formulation and Medication Adherence. <i>Journal of General Internal Medicine</i> , 2020, 35, 354-356.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Integration of Diabetes Technology in Clinical Practice. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 69-77.	1.2	6
20	Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. <i>Diabetologia</i> , 2020, 63, 229-241.	2.9	56
21	Comprehensive Pulmonary Safety Review of Inhaled Technosphere [®] Insulin in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2020, 40, 973-983.	1.1	7
22	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. <i>Obesity</i> , 2020, 28, 1678-1686.	1.5	47
23	Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. <i>Diabetes Care</i> , 2020, 43, 2713-2720.	4.3	15
24	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2397.	3.8	191
25	Do menopausal status and APOE4 genotype alter the long-term effects of intensive lifestyle intervention on cognitive function in women with type 2 diabetes mellitus?. <i>Neurobiology of Aging</i> , 2020, 92, 61-72.	1.5	12
26	Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1083-1093.	2.2	5
27	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e130-e138.	1.8	22
28	Weight Loss Experiences of African American, Hispanic, and Non-Hispanic White Men and Women with Type 2 Diabetes: The Look AHEAD Trial. <i>Obesity</i> , 2019, 27, 1275-1284.	1.5	20
29	Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2440-2449.	2.2	20
30	The Affordable Care Act and Health Insurance Coverage Among People With Diagnosed and Undiagnosed Diabetes: Data From the National Health and Nutrition Examination Survey. <i>Diabetes Care</i> , 2019, 42, e179-e180.	4.3	11
31	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019, 42, 919-930.	4.3	51
32	Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1752-1756.	2.2	1
33	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
34	Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6279-6290.	1.8	23
35	Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. <i>Diabetes Therapy</i> , 2018, 9, 583-612.	1.2	267
36	Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD ² , ⁴ and ⁵ Trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1490-1498.	2.2	40

#	ARTICLE	IF	CITATIONS
37	Diabetes Empowerment Council: Integrative Pilot Intervention for Transitioning Young Adults With Type 1 Diabetes. <i>Global Advances in Health and Medicine</i> , 2018, 7, 216495611876180.	0.7	14
38	Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The Look AHEAD Study. <i>Diabetes Care</i> , 2018, 41, 1040-1048.	4.3	47
39	Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1552-1559.	1.7	39
40	Advances in Glucose Monitoring and Automated Insulin Delivery: Supplement to Endocrine Society Clinical Practice Guidelines. <i>Journal of the Endocrine Society</i> , 2018, 2, 1214-1225.	0.1	16
41	Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD 2, 4 and 5 trials". <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2319-2320.	2.2	0
42	HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. <i>Diabetes Care</i> , 2018, 41, 1981-1990.	4.3	138
43	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018, 41, 1970-1980.	4.3	170
44	Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 571-575.	2.4	68
45	Exercise management in type 1 diabetes: a consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 377-390.	5.5	588
46	Resilient, Empowered, Active Living with Diabetes (REAL Diabetes) study: Methodology and baseline characteristics of a randomized controlled trial evaluating an occupation-based diabetes management intervention for young adults. <i>Contemporary Clinical Trials</i> , 2017, 54, 8-17.	0.8	17
47	REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 538-545.	4.3	230
48	The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 171-180.	4.3	91
49	Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. <i>Current Medical Research and Opinion</i> , 2017, 33, 639-645.	0.9	20
50	Clinical and Psychosocial Outcomes of a Structured Transition Program Among Young Adults With Type 1 Diabetes. <i>Journal of Adolescent Health</i> , 2017, 60, 212-218.	1.2	38
51	Engagement and outcomes in a digital Diabetes Prevention Program: 3-year update. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000422.	1.2	79
52	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2337-2348.	13.9	322
53	Objectively Assessed Physical Activity and Weight Loss Maintenance among Individuals Enrolled in a Lifestyle Intervention. <i>Obesity</i> , 2017, 25, 1903-1909.	1.5	36
54	Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. <i>Diabetes Care</i> , 2017, 40, 1622-1630.	4.3	283

#	ARTICLE	IF	CITATIONS
55	A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes. <i>Journal of the Endocrine Society</i> , 2017, 1, 1445-1460.	0.1	75
56	Therapy of Type 1 Diabetes Mellitus. , 2017, , 1-24.		0
57	Authorsâ€™ reply to Bosco-LÃ©vy and Salvo. <i>BMJ, The</i> , 2016, 354, i4330.	3.0	0
58	Characteristics of youth with type 1 diabetes (T1D) with and without a parent with T1D in the T1D exchange clinic registry. <i>Journal of Diabetes</i> , 2016, 8, 834-838.	0.8	5
59	The relationship of social support with treatment adherence and weight loss in <sc>L</sc>atinos with type 2 diabetes. <i>Obesity</i> , 2016, 24, 568-575.	1.5	38
60	Increasing Patient Acceptance and Adherence Toward Insulin. <i>Postgraduate Medicine</i> , 2016, 128, 11-20.	0.9	3
61	Hypoglycemia in Older Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 765-771.	2.4	29
62	The Impact of Real-Time Continuous Glucose Monitoring in Patients 65 Years and Older. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 892-897.	1.3	44
63	Diabetes Technologyâ€™ Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3922-3937.	1.8	165
64	Four-Year Physical Activity Levels among Intervention Participants with Type 2 Diabetes. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 2437-2445.	0.2	37
65	Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1123-1128.	1.2	126
66	Diabetic Ketoacidosis With Canagliflozin, a Sodiumâ€™ Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 532-538.	4.3	83
67	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 603-610.	4.3	126
68	Clinical and Economic Impact of a Digital, Remotely-Delivered Intensive Behavioral Counseling Program on Medicare Beneficiaries at Risk for Diabetes and Cardiovascular Disease. <i>PLoS ONE</i> , 2016, 11, e0163627.	1.1	41
69	Biosimilars and New Insulin Versions. <i>Endocrine Practice</i> , 2015, 21, 1387-1394.	1.1	16
70	Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. <i>BMJ, The</i> , 2015, 351, h6223.	3.0	30
71	Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000074.	1.2	21
72	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	2.9	598

#	ARTICLE	IF	CITATIONS
73	Primary Care Medical Home Experience and Health-Related Quality of Life Among Adult Medicaid Patients with Type 2 Diabetes. <i>Journal of General Internal Medicine</i> , 2015, 30, 161-168.	1.3	16
74	Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 476-481.	4.3	187
75	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015, 38, 1687-1693.	4.3	645
76	Diabetes and Cardiovascular Disease Risk Factors as Influenced by Race and Ethnic Background. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	1
77	Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. <i>Diabetologia</i> , 2015, 58, 862-870.	2.9	62
78	Patient Perspectives on Peer Mentoring. <i>The Diabetes Educator</i> , 2015, 41, 59-68.	2.6	26
79	Let's Empower and Prepare (LEAP): Evaluation of a Structured Transition Program for Young Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1412-1419.	4.3	79
80	Understanding the sources of diabetes distress in adults with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 572-577.	1.2	253
81	Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. <i>Diabetes Care</i> , 2015, 38, 716-722.	4.3	95
82	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	4.3	2,326
83	Long-Term Outcomes of a Web-Based Diabetes Prevention Program: 2-Year Results of a Single-Arm Longitudinal Study. <i>Journal of Medical Internet Research</i> , 2015, 17, e92.	2.1	157
84	Response to Comment on Wong et al. Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry. <i>Diabetes Care</i> 2014;37:2702-2709. <i>Diabetes Care</i> , 2015, 38, e61-e61.	4.3	1
85	Healthcare Costs and Adherence Associated with Human Regular U-500 Versus High-Dose U-100 Insulin in Patients with Diabetes. <i>Endocrine Practice</i> , 2014, 20, 663-670.	1.1	27
86	Depression in Adults in the T1D Exchange Clinic Registry. <i>Diabetes Care</i> , 2014, 37, 1563-1572.	4.3	65
87	Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. <i>Diabetes Care</i> , 2014, 37, 2034-2054.	4.3	727
88	Do Experiences Consistent With a Medical-Home Model Improve Diabetes Care Measures Reported by Adult Medicaid Patients?. <i>Diabetes Care</i> , 2014, 37, 2565-2571.	4.3	17
89	The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2822-2829.	4.3	33
90	GLP-1 Provoked Severe Hypoglycemia in an Individual With Type 2 Diabetes and a Benign Insulinoma. <i>Diabetes Care</i> , 2014, 37, e177-e178.	4.3	7

#	ARTICLE	IF	CITATIONS
91	Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes. <i>Aging Clinical and Experimental Research</i> , 2014, 26, 115-121.	1.4	7
92	Translating the Diabetes Prevention Program into an Online Social Network. <i>The Diabetes Educator</i> , 2014, 40, 435-443.	2.6	111
93	Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. <i>Diabetes Care</i> , 2014, 37, 1544-1553.	4.3	178
94	Diabetes Empowerment Council (DEC): Development and Pilot Testing of an Innovative Mind-Body Group Intervention for Young Adults with Type 1 Diabetes. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, A69-A69.	2.1	4
95	Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. <i>Diabetes Care</i> , 2014, 37, 2548-2556.	4.3	144
96	“We Are All Gonna Get Diabetic These Days” <i>The Diabetes Educator</i> , 2014, 40, 648-658.	2.6	15
97	Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry. <i>Diabetes Care</i> , 2014, 37, 2702-2709.	4.3	278
98	Trial to Examine Text Message-Based mHealth in Emergency Department Patients With Diabetes (TEXT-MED): A Randomized Controlled Trial. <i>Annals of Emergency Medicine</i> , 2014, 63, 745-754.e6.	0.3	224
99	Cardiovascular health: associations with race/ethnicity, nativity, and education in a diverse, population-based sample of Californians. <i>Annals of Epidemiology</i> , 2013, 23, 388-394.	0.9	22
100	Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. <i>Journal of Medical Economics</i> , 2013, 16, 529-538.	1.0	31
101	Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3411-3419.	1.8	258
102	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 145-154.	13.9	2,294
103	Intensive Weight Loss Intervention in Older Individuals: Results from the Action for Health in Diabetes Type 2 Diabetes Mellitus Trial. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 912-922.	1.3	52
104	Continuous Glucose Monitoring Pilot in Low-Income Type 1 Diabetes Patients. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 855-858.	2.4	41
105	Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 562-578.	1.3	104
106	Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy. <i>Annals of Medicine</i> , 2012, 44, 836-846.	1.5	29
107	A Mobile Health Intervention for Inner City Patients with Poorly Controlled Diabetes: Proof-of-Concept of the TEXT-MED Program. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 492-496.	2.4	136
108	Challenges in Applying Diabetes Technology to Clinical Care. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 849-850.	2.4	0

#	ARTICLE	IF	CITATIONS
109	Managing Diabetes in the Middle-Aged Patient When Loss of Glycemic Control Occurs. The Diabetes Educator, 2012, 38, 13S-21S.	2.6	0
110	Diabetes Management For Low-Income Patients In Los Angeles: Two Strategies Improved Disease Control In The Short Term. Health Affairs, 2012, 31, 168-176.	2.5	15
111	Immigration Disparities in Cardiovascular Disease Risk Factor Awareness. Journal of Immigrant and Minority Health, 2012, 14, 918-925.	0.8	38
112	Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population. Diabetes Technology and Therapeutics, 2012, 14, 904-911.	2.4	74
113	Trends in diabetes-related visits to US EDs from 1997 to 2007. American Journal of Emergency Medicine, 2012, 30, 754-758.	0.7	14
114	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care, 2012, 35, 1364-1379.	4.3	3,077
115	Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trial. Journal of Bone and Mineral Research, 2012, 27, 619-627.	3.1	68
116	The Role of Farmersâ€™ Markets in Two Low Income, Urban Communities. Journal of Community Health, 2012, 37, 554-562.	1.9	67
117	Diabetes Care for Emerging Adults: Recommendations for Transition From Pediatric to Adult Diabetes Care Systems. Diabetes Care, 2011, 34, 2477-2485.	4.3	477
118	Beyond the Monofilament for the Insensate Diabetic Foot. Diabetes Care, 2011, 34, 1041-1046.	4.3	55
119	Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care, 2011, 34, 1481-1486.	4.3	1,342
120	Incretin-Based Therapies: Review of Current Clinical Trial Data. American Journal of Medicine, 2010, 123, S28-S37.	0.6	97
121	Therapy of Type 1 Diabetes Mellitus. , 2010, , 709-729.		0
122	Do We Really Need Continuous Glucose Monitoring?. Diabetes Technology and Therapeutics, 2009, 11, S-128-S-130.	2.4	2
123	Clinical and Behavioral Correlates of Achieving and Maintaining Glycemic Targets in an Underserved Population With Type 2 Diabetes. Diabetes Care, 2009, 32, 54-56.	4.3	19
124	Re-emergence of another vaccine-preventable disease?â€”Two cases of rubella in older adults. Journal of Clinical Virology, 2009, 46, 98-100.	1.6	6
125	Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleveland Clinic Journal of Medicine, 2009, 76, S20-S27.	0.6	23
126	Clinical Application of Emerging Sensor Technologies in Diabetes Management: Consensus Guidelines for Continuous Glucose Monitoring (CGM). Diabetes Technology and Therapeutics, 2008, 10, 232-246.	2.4	114

#	ARTICLE	IF	CITATIONS
127	Male Anorgasmia Treated with Oxytocin. <i>Journal of Sexual Medicine</i> , 2008, 5, 1022-1024.	0.3	62
128	Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-year results of the Look AHEAD trial. <i>Diabetes Care</i> , 2007, 30, 1374-1383.	4.3	1,369
129	Case Study 2. <i>The Diabetes Educator</i> , 2007, 33, 14S-19S.	2.6	3
130	Food and Park Environments: Neighborhood-level Risks for Childhood Obesity in East Los Angeles. <i>Journal of Adolescent Health</i> , 2007, 40, 325-333.	1.2	144
131	Running a Diabetes Clinic. , 2006, , 583-592.		0
132	Short and longer term outcomes of a diabetes disease management program in underserved Latino patients. <i>Current Medical Research and Opinion</i> , 2005, 21, 1935-1941.	0.9	7
133	Considerations for treating dyslipidemia in special diabetic populations. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 88-95.	1.7	1
134	Treating diabetes: cardiovascular benefits of antidiabetes drugs. <i>American Journal of Managed Care</i> , 2002, 8, S219-28; quiz S229-32.	0.8	3
135	Diabetes Disease Management: Past, Present, and Future. , 2001, 11, 86-93.		2
136	Diagnosing diabetes in 2000. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2000, 7, 31-37.	0.6	0
137	Diagnosing diabetes in 2000. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2000, 7, 31-37.	0.6	2
138	Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. <i>Journal of General Internal Medicine</i> , 2000, 15, 551-555.	1.3	67
139	Relationship Between Fasting Plasma Glucose and Glycosylated Hemoglobin. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1203.	3.8	164
140	Antihypertensive Agents in Diabetic Patients. <i>Archives of Internal Medicine</i> , 1999, 159, 541.	4.3	5
141	Use of Glycosylated Hemoglobin Levels for Diagnosing Diabetes Mellitus-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1997, 277, 211.	3.8	0
142	An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus. <i>American Journal of Medicine</i> , 1997, 102, 99-110.	0.6	216
143	Death and Medicine: A personal account. <i>American Journal of Medicine</i> , 1990, 89, 81-82.	0.6	4